News Purple Biotech Ltd

Equities

PPBT

IL0007650166

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:15 2024-07-11 am EDT			5-day change	1st Jan Change
16.3 ^ILa	+4.49%		+5.16%	-48.90%

Jun. 27	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
Jun. 27	Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech : Immediate report on other matter	Jul. 02	PU
Purple Biotech : Immediate Report	Jul. 02	PU
Purple Biotech : Immediate Report	Jul. 02	PU
Purple Biotech : Report Of Foreign Private Issuer Form 6 K	Jul. 02	PU
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	Jun. 27	MT
Purple Biotech : Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	Jun. 27	PU
Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	Jun. 27	CI
Purple Biotech : Immediate Report of Meeting	Jun. 26	PU
Purple Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Form 6 K	Jun. 26	PU
6K: The Tel Aviv District Court dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against us, our executive directors and certain of our present and former directors in February 2017	Jun. 20	PU
Purple Biotech : Immediate Report	Jun. 05	PU
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer	Jun. 01	AQ
Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer	Jun. 01	CI
Purple Biotech Reports First Quarter 2024 Financial Results	May. 21	AQ
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting	Apr. 25	CI
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	Mar. 28	AQ
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology	Mar. 14	CI
Purple Biotech : Immediate Report	Mar. 06	PU
6K:Fourth Quarter and Full-Year 2023 Financial Results	Mar. 05	PU
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Purple Biotech Ltd

Equities

PPBT

IL0007650166

Summary

Filters